LGCY vs SKIN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LGCY exhibits strong fundamental health with a Piotroski F-Score of 7/9 and exceptional growth metrics, including 40.7% YoY revenue growth and 50% earnings growth. While the current price of $11.21 is above the conservative Graham Number ($7.02), it remains significantly discounted relative to its growth-based intrinsic value of $17.70. The company maintains a very healthy balance sheet with low debt (D/E 0.34) and high liquidity (Current Ratio 2.98). Despite short-term technical weakness and minor insider selling, the underlying profitability (ROE 20.06%) and valuation relative to sector peers make it an attractive growth play.
The Beauty Health Company (SKIN) presents a high-risk profile characterized by a stable Piotroski F-Score of 5/9 but severely compromised financial health. While valuation metrics like Price/Sales (0.39) and Forward P/E (8.30) appear attractive, they are overshadowed by an extreme Debt/Equity ratio of 6.20 and negative revenue growth. The stock is in a severe long-term downtrend, losing over 90% of its value over 3 and 5 years, suggesting the market is pricing in significant solvency or growth risks.
Compare Another Pair
Related Comparisons
LGCY vs SKIN: Head-to-Head Comparison
This page compares Legacy Education Inc. (LGCY) and The Beauty Health Company (SKIN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.